 Antiretroviral naïve patients with 350 xE6l CD4 cells and a HIV-viral load of 30.000 copml are started on combivir and Kaletra . When patients have reached an undetectable viral load of 50 copml on two consecutive occasions at least at week 12, but no later than week 24, they are randomised in either continuation with CombivirKaletra or switch to Trizivir twice daily one pill during 96 weeks. All patients randomised in the combivirKaletra arm are eligible to switch to Trizivir at any post randomisation visit when they reach predefined switch criteria for elevated levels of fasting glucose or lipids. 